Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | JUN | P05412 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 1.00 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.59 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.59 |
| ▸ | APAF1 | O14727 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598852 | 1.00 | MAPT (1.00) | MAPTRAB9AKDM4EJUNNFKB1 | |
| Hydrochloric Acid SCHEMBL11971085 | 0.98 | MAPT (0.96) | MAPTRAB9AKDM4EJUNNFKB1 | |
| Hydrochloric Acid SCHEMBL11971079 | 0.98 | MAPT (0.96) | MAPTRAB9AKDM4EJUNNFKB1 | |
| SCHEMBL16093039 | 0.94 | MAPT (0.89) | MAPTRAB9AKDM4EJUNNFKB1 | |
| SCHEMBL28356916 | 0.90 | MAPT (0.81) | MAPTRAB9AKDM4EJUNNFKB1 | |
| SCHEMBL334614 | 0.86 | RAB9A (0.76) | MAPTRAB9AKDM4EJUNNFKB1 | |
| SCHEMBL755249 | 0.86 | RAB9A (0.76) | MAPTRAB9AKDM4EJUNNFKB1 | |
| SCHEMBL334615 | 0.86 | RAB9A (0.76) | MAPTRAB9AKDM4EJUNNFKB1 | |
| SCHEMBL29416684 | 0.86 | RAB9A (0.76) | MAPTRAB9AKDM4EJUNNFKB1 | |
| SCHEMBL6848207 | 0.85 | RAB9A (0.73) | MAPTRAB9AKDM4EJUNNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | disclosed |
| US-10744124-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-18 | — | — | US | disclosed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | disclosed |
| EP-3275465-B1 | THERAPEUTIC COMPOSITIONS COMPRISING A COMBINATION OF A HARMINE AND ISOVANILLIN COMPONENT | ANKH LIFE SCIENCES LTD (IE) | 2020-05-06 | — | — | EP | disclosed |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2020-03-03 | — | — | US | disclosed |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2019-11-12 | — | — | US | disclosed |
| US-20190231756-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | ANKH LIFE SCIENCES LIMITED (IE) | 2019-08-01 | — | — | US | disclosed |
| EP-3188721-B1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LTD (IE) | 2019-06-12 | — | — | EP | disclosed |
| US-20140271470-A1 | TARGETED THERANOSTICS FOR METASTATIC PROSTATE CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2014-09-18 | — | — | US | disclosed |
| US-20140271470-A1 | TARGETED THERANOSTICS FOR METASTATIC PROSTATE CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2014-09-18 | — | — | US | disclosed |
| US-20120214996-A1 | COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-08-23 | — | — | US | disclosed |
| US-20120214996-A1 | COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-08-23 | — | — | US | disclosed |
| US-20120214996-A1 | COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-08-23 | — | — | US | disclosed |
| WO-2011033115-A2 | COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-03-24 | — | — | WO | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744124-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | MAPT 497/4885RAB9A 2823/4885KDM4E 3586/4885 |
| US-20190231756-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | MAPT 198/4885RAB9A 2274/4885KDM4E 1842/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | MAPT 448/4885RAB9A 2062/4885KDM4E 3658/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | MAPT 497/4885RAB9A 2823/4885KDM4E 3586/4885 |
| US-20140271470-A1 | TARGETED THERANOSTICS FOR METASTATIC PROSTATE CANCER | KLK3, ACP3, FOLH1 | MAPT 296/4885RAB9A 1978/4885KDM4E 4234/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | MAPT 497/4885RAB9A 2823/4885KDM4E 3586/4885 |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | MAPT 198/4885RAB9A 2274/4885KDM4E 1842/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | MAPT 497/4885RAB9A 2823/4885KDM4E 3586/4885 |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | MAPT 497/4885RAB9A 2823/4885KDM4E 3586/4885 |
| US-20120214996-A1 | COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES | TST, PDXK, TBCB | MAPT 4863/4885RAB9A 2226/4885KDM4E 854/4885 |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | MAPT 198/4885RAB9A 2274/4885KDM4E 1842/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | MAPT 2066/4885RAB9A 2661/4885KDM4E 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.